PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model

Blood

Volumn 117, Issue 7, 2011, Pages 2241-2246

  Reilly, Michael P ^a   Sinha, Uma ^b   André, Pierrette ^a   Taylor, Scott M ^a   Pak, Yvonne ^b   DeGuzman, Francis R ^b   Nanda, Nisha ^b   Pandey, Anjali ^b   Stolla, Moritz ^a   Bergmeier, Wolfgang ^a   McKenzie, Steven E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Portola Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; MONOCLONAL ANTIBODY; PROTEIN KINASE SYK INHIBITOR; PRT 060318; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSGENIC MOUSE;

EID: 79951849374     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274969     Document Type: Article

References (32)

1. Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost. 2000;26(suppl 1):5-21.
2. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-135. (Pubitemid 40974717)
3. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535-555. (Pubitemid 36645375)
4. Visentin GP. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost. 1999;82(2):448-456.
5. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol. 2006;81(1):36-44. (Pubitemid 43077211)
6. Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol. 1998;16(3):237-247. (Pubitemid 28450581)
7. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82(2):439-447.
8. Reilly MP, Taylor SM, Hartman NK, et al. Heparininduced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
9. Xiao Z, Visentin GP, Dayananda KM, Neelamegham S. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood. 2008;112(4):1091-1100.
10. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97(10):3300-3302.
11. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98(4):1252-1254.
12. Indik ZK, Salehuddin M, McKenzie SE, Kelly C, Levinson AI, Schreiber AD. Human Fc gamma RII: the structure of the Fc gamma RII cytosolic domain governs phagocytic function. Trans Assoc Am Physicians. 1992;105:214-221.
13. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997;16(9):2333-2341. (Pubitemid 27258634)
14. Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood. 1992;80(9):2261-2268.
15. Hisamichi H, Kawazoe S, Naito R, et al. Synthetic studies on heteroaryl carboxamide derivatives as novel Syk inhibitors. 226th American Chemical Society National Meeting, New York, NY, 2003.
16. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111(4):2230-2237. (Pubitemid 351451430)
17. Rauova L, Poncz M, McKenzie SE, et al. Ultra-large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131-138. (Pubitemid 40053074)
18. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95(5):1533-1540. (Pubitemid 30120810)
19. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925-930.
20. Reilly MP, Taylor SM, Franklin C, et al. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost. 2006;4(12):2687-2694. (Pubitemid 44741566)
21. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999;162(7):4311-4318. (Pubitemid 29314823)
22. Delaney S, Sinha U, Nanda N, et al. Specific pharmacological targeting of the Syk kinase activity in platelets: a novel, safe anti-thrombotic strategy. Blood. 2008;112(11):409.
23. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99(5):819-829. (Pubitemid 351705298)
24. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost. 2008;99(5):830-839. (Pubitemid 351705299)
25. Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 2009;113(11):2508-2516.
26. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
27. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154-3160.
28. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor, blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998-1008.
29. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58(11):3309-3318.
30. Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
31. Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost. 2009;7(7):1192-1199.
32. Gardiner EE, Karunakaran D, Arthur JF, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa. Blood. 2008;111(1):165-174.